2 active not recruiting, 2 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 2 |
Follow Stage IVB Osteosarcoma AJCC v7: new trials by email Literature Review of Stage IVB Osteosarcoma AJCC v7 trials Research Report on Stage IVB Osteosarcoma AJCC v7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma Denosumab, Laboratory Biomarker Analysis, Pharmacological Study - Metastatic Osteosarcoma, Recurrent Osteosarcoma | Phase 2 | Completed | Children's Oncology Group | 56 | 2015-11-21 | 2024-01-22 |
| Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma Cabozantinib S-malate, Laboratory Biomarker Analysis - Metastatic Ewing Sarcoma, Metastatic Osteosarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2014-12-19 | 2026-08-18 |
Osteosarcoma (4) · Sarcoma, Ewing (3) · Central Nervous System Neoplasms (2) · Ependymoma (2) · Glioma (2) · Hepatoblastoma (2) · Histiocytosis, Langerhans-Cell (2) · Lymphoma, Non-Hodgkin (2) · Medulloblastoma (2) · Neuroblastoma (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Rhabdoid Tumor (2) · Rhabdomyosarcoma (2) · Sarcoma (2) · Wilms Tumor (2)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Bone Tissue (4) · Neoplasms, Connective Tissue (4) · Neoplasms, Connective and Soft Tissue (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genetic Diseases, Inborn (2) · Hemic and Lymphatic Diseases (2) · Histiocytosis (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Kidney Diseases (2) · Kidney Neoplasms (2)
LY3023414 (2) · Magnetic Resonance Spectroscopy (2) · Phantoms, Imaging (2) · Specimen Handling (2) · X-Rays (2) · Biopsy (1) · Denosumab (1) · Nuclear Medicine Department, Hospital (1) · QL1206 (1) · Vemurafenib (1) · cabozantinib (1) · ensartinib (1) · erdafitinib (1) · ivosidenib (1) · larotrectinib (1)
National Cancer Institute (NCI) (3) · Children's Oncology Group (1)
Puerto Rico (3) · United States (3) · Canada (2) · Australia (1) · France (1)
Antoine Italiano (1) · Donald W Parsons (1) · Katherine A Janeway (1) · Theodore W Laetsch (1)
PMID 31401903, PMID 32078813, PMID 33591402, PMID 35353553, PMID 41166674, PMID 42686334
U10CA180886 (3)